COPENHAGEN--Novo Nordisk will launch its hugely popular anti-obesity drug Wegovy in Japan on Feb. 22 next year, its first launch in Asia, the company said on Thursday, even as it struggles to keep ...
The first clinical trial of its kind found the weekly jab semaglutide, also known as Ozempic and Wegovy, cuts the amount people drink in one day by about 40% and dramatically reduced the desire ...
2-Year U.S. Treasury Note Continuous Contract $102.742-0.020-0.02% 5-Year U.S. Treasury Note Continuous Contract $106.453-0.055-0.05% 10-Year U.S. Treasury Note Continuous Contract $109.203-0.109 ...
2-Year U.S. Treasury Note Continuous Contract $102.602 0.047 0.05% 5-Year U.S. Treasury Note Continuous Contract $105.977 0.102 0.10% 10-Year U.S. Treasury Note Continuous Contract $108.391 0.125 ...
Visit us on Facebook. Opens in a new tab or window Visit us on X. Opens in a new tab or window Visit us on Instagram. Opens in a new tab or window Visit us on LinkedIn. Opens in a new tab or ...
AXSM stock rises 20% as it settles Auvelity patent litigation with Teva, protecting the drug's exclusivity in the United States at least until Sept. 30, 2038. Shares in the brain drug developer ...
Japanese firm Metaplanet Inc. has raised $25.9 million (¥4 billion) through the issuance of zero-interest, unsecured bonds, seeking to expand its Bitcoin (BTC) holdings. The Tokyo-based firm confirmed ...
After hours: February 14 at 6:23:03 PM EST Loading Chart for SKYE ...
GLP-1 agonists currently licensed for the treatment of obesity include a higher-dose version of Victoza called Saxenda (liraglutide) and a higher-dose version of Ozempic called Wegovy (semaglutide).
After hours: 14 February at 7:59:39 pm GMT-5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results